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Summary 
We determined the DNA sequences of the internal transcribed spacer 1 and 2 (ITS 1and 
2), the 5.8S rRNA gene and most of the 28S rRNA gene of Poria cocos for the first time, 
and conducted analysis of 20 samples including cultured mycelias and crude drug 
materials obtained from various localities and markets. Direct sequencing of the ITS 1 
and 2 regions of the samples, except for four wild samples, showed that they had 
identical DNA sequences for ITS 1 and 2 with nucleotide lengths of 997 bps and 460 
bps, respectively. By cloning, the four wild samples were found to have combined 
sequences of common ITS sequences with 1 or 2-base-pair insertions. Altogether both 
ITS 1 and 2 sequences were substantially longer than those of other fungal crude drugs 
such as Ganoderma lucidum and Polyporus umbellatus. Thus, Poria cocos could be 
distinguished from these crude drugs and fakes by comparing the nucleotide length of 
PCR products of ITS 1 and 2. Contrary to the basic homogeneity in ITS 1 and 2, three 
types (Group 1, 2, and 3) of the 28S rRNA gene with distinctive differences in length 
and sequence were found. Furthermore, Group 1 could be divided into three subgroups 
depending on differences at nucleotide position 690. Products with different types of 
28S rRNA gene were found in crude drugs from Yunnan and Anhui Provinces as well 
as the Korean Peninsula, suggesting that the locality of the crude drugs does not 
guarantee genetic uniformity. The result of DNA typing of Poria cocos may help 
discrimination of the quality of the crude drug by genotype.  
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Hoelen, a dried sclerotium of Poria cocos Wolf (Polyporaceae) has been used as a 
crude drug in both Chinese and Japanese traditional medicines (Kampo).  In addition to 
the traditional use, recent studies have shown the therapeutic potential of Hoelen as a 
cytokine secretion modulator1) and an anticancer agent2). In Kampo medicine, Hoelen is 
prescribed in many important formulations, and about 700 tons per year is consumed in 
the Japanese market, mostly imported from China and some from the Korean Peninsula 
3). Recently, cultivated Chinese Hoelens accounted for most of Japanese market. 
However, the harvests of cultivated Hoelens decreased greatly in China in 2004. The 
reason for this decrease was due to the forest conservation activities by the government 
of Anhui Province, one of the main cultivation centers of Hoelen 4). Therefore, it is 
thought that fake Hoelen will emerge in the market. Furthermore, the locality of the 
crude drug has long been believed to specify its quality. Hoelen produced in Yunnan 
province, for example, is renowned for its medicinal properties5) 6). However, the 
relationship between the quality of the crude drug and its locality has not yet been 
clarified. Moreover, there is no evidence that Hoelens from the same locality have the 
same genetic background. Molecular genetic criteria have been introduced to classify 
the crude drug species and intraspecific variation in recent years. DNA sequences of 
appropriate regions in the Poria cocos genome could be ultimate molecular markers of 
the crude drug. There was no difference between Chinese and Japanese Poria cocos in 
the nucleotide sequence of the 18S rRNA gene, while mutual aversion phenomena were 
observed between them 7). Nucleotide analysis of the nuclear ribosomal ITS region and 
28S rRNA gene may provide more information about inter- and intraspecific variations 
of the fungus. In the present paper, we report the DNA sequences of the complete ITS 
region and most of the 28S rRNA gene sequences of Poria cocos, and the results of the 
analysis of 20 Poria cocos samples including cultured mycelia and crude drug materials 
obtained from various localities. 
 
MATERIALS AND METHODS 
Fungal Materials   
The 20 samples used in this study including cultured mycelia of Poria cocos and 
Hoelens obtained from various localities are summarized in Table 1. The cultured 
mycelia were derived from fresh Hoelen samples. Fresh Japanese Hoelen samples were 
collected by us. Two Hoelen samples from the Korean Peninsula, Korea-1 and Korea-2, 
were purchased in Kyungdong market. Fresh Hoelens used to derive cultured mycelia 
Sekkou-1 and -2, and crude drug Korea-3 (Korean Peninsula) were obtained from 
Tochimoto-Tenkaido Co. Ltd. A Hoelen sample from Guizhou, Kishu, was purchased in 
Chong-Qing-Zhong-Yao-Zhuan-Ye market. A Hoelen sample from Yunnan, Yunnan-2, 
was purchased from Xing-Lin Co. Ltd. in the An-Guo crude drug market. Hoelen 
samples, Yunnan-1, Yunnan-3, Yunnan-4 (Yunnan), and Shisen (Sichuan) were 
obtained from He-Hua-Chi via Kanebo Pharmaceutical Co. Ltd. Anhui Hoelen samples 
Anki-1, -2, and -3 were obtained from Uchida Wakanyaku Co. Ltd. All of these crude 
drug specimens were stored in the Herbarium of the Laboratory of the Herbal Medicine 
and Natural Resources of the Graduate School of Natural Science and Technology, 
Kanazawa University. Ganoderma  (Ganoderma lucidum (Leiss. ex. Fr.) Karst. and 




 Isolation of Total DNA  
Total DNA was extracted from 2-4 g of crude drug material ground into fine powder. 
The resulting crude drug powder was washed with a 1 ml of washing buffer containing 
0.1 M Tris-HCl (pH 8.0), 0.35 M Sorbitol, 10% polyethylene glycol, 2% 
mercaptoethanol, and total DNA was extracted using a DNeasy Plant Mini Kit 
according to the manufacturer’s protocol. Total DNA was extracted from 200-400 mg 
of fresh cultured mycelia material using a DNeasy Plant Mini Kit (Qiagen), according 
to the manufacturer’s protocol with minor modifications. 
 
PCR Amplification 
Polymerase chain reaction (PCR) was performed using 30-100 ng of total DNA as the 
template in 25 ȣl of a reaction mixture containing 2.5 µl 10PCR buffer for KOD 
-Plus-, 0.2 mM of each dNTP, 1.0 µM of MgSO4, 0.5 units KOD -Plus- polymerase 
(Toyobo), and 0.4 mM of each primer. Primers used are shown in Table 2. 
Amplification was carried out under the following conditions: pre-heating at 94Υ for 2 
min; 30 cycles of denaturation at 94Υ for 15 s, annealing at 55Υ for 30 s and 
elongation at 68Υ for 2 min; a final elongation at 68Υ for 5 min. One tenth volume of 
the PCR products was analyzed by agarose gel electrophoresis and then the remaining 
part was purified using a QIAquick PCR Purification Kit (Qiagen).  
 
Sequencing Reaction 
The purified PCR product was subjected to direct sequencing using a BigDye 
Terminator Cycle Sequencing Kit (Applied Biosystems) using an ABI PRISM 310 
sequencer (Applied Biosystem). The DNA sequences were aligned using ‘DNASIS’ 
version 3.0 (Hitachi). 
 
 
Cloning of PCR products 
Total DNA of Shikoku and Yunnan-1, were amplified by using a tagged primer set, p 
and q. Those of L2 and Korea-2, were amplified by using primer set, p and i, and those 
with combined sequences in the 28S rRNA gene, L2, Shikoku and Yunnan-1, were 
amplified by using primer sets h and j or r and s. After purification using a QIAquick 
PCR purification kit, the PCR products (100-200 ng) were digested with BamHI and 
HindIII (TaKaRa) in a 10 µL-reaction reaction mixture containing 20 mM Tris-HCl (pH 
8.5), 10 mM MgCl2, 1 mM dithiothreitol, and 0.1 M KCl at 37Υ for 1 hr, and then the 
reaction mixture was heated to 70Υ for 15 min. Four µL of the reaction mixtures were 
combined with 5 ng of pBluescript SK(-)plasmid digested with the same enzymes and 5 
µL of DNA Ligation Kit Ver.2.1 (TaKaRa). The ligation reaction was performed at 
16 Υ overnight. Competent cells (Competent high DH5α, TOYOBO) were transformed 
with the ligated product according to the manufacturer’s protocol. The transformed cells 
were spread on LB / Amp plates (2% tripton, 1% yeast extract, 2% NaCl, 3% agar, and 
10 µg/mL ampicillin) and incubated at 37Υ overnight. Bacterial colonies were picked 
up separately, and sub-cultured in liquid LB / Amp medium. After overnight-incubation, 




Restriction fragment length polymorphism experiment for the discrimination of Group-1, 
-2, and -3 
PCR products amplified by using primer sets of k and o or k and l were purified using a 
QIAquick PCR purification kit and then digested with 15 units of restriction enzyme 
either BamHI or DraI (Takara) at 37Υ for 1 hour. Reaction mixtures were separated by 
electrophoresis in 2% agarose gels with 1×TAE buffer. After 1 hour immersion in 0.5 




Sequencing Analysis of the ITS Regions  
Direct sequencing of PCR products of the ITS 1 and 2 regions revealed that 16 of 20 
Poria cocos samples (the exceptions were L2, Shikoku, Korea-2, and Yunnan-1) had 
identical sequences with the nucleotide lengths of 997 bps and 460 bps, respectively 
(Table 3). By cloning the PCR products of L2, Shikoku, Korea-2, and Yunnan-1, they 
were found to have overlapping of the common sequence and sequences with 1 or 2 
base-pair-insertions; a 2 base-pair-insertion at nucleotide positions 637-638 of ITS1 in 
Yunnan-1, and 1 base-pair-insertions at nucleotide position 419 of ITS2 in L2, at 
nucleotide position 657 of ITS1 in Shikoku, and at nucleotide position 453 of ITS2 in 
Korea-2. Altogether, the nucleotide lengths of ITS 1 and 2 of these Poria cocos samples 
were substantially longer in comparison with other fungus crude drugs, such as 
Ganoderma lucidum and Polyporu umbellatus; the lengths of their ITS 1 and 2 
sequences were reported within the ranges of 190-220 bps and 170-200 bps, 
respectively9) 10) 11) 12). When the PCR products amplified from the ITS 1 region using 
primer set a and d of the Poria cocos samples and those of Ganoderma lucidum and 
Polyporus umbellatus were compared, they could be clearly distinguished from each 
other by agarose gel electrophoresis (Fig. 1).  
 
Sequencing analysis of 28S rRNA Gene  
About nine tenths of the 28S rRNA gene sequence was determined by the nucleotide 
sequence alignment of PCR products amplified using primer sets g and j, k and m, and 
n and o. The results revealed that the nucleotide length of this region varied as shown in 
Table 3. By cloning the PCR products, the 28S rRNA gene sequence of 2 Japanese 
samples, L2 and Shikoku, and Yunnan-1 (Yunnan) were found to have overlapping of 
the common sequence with 2865 bps and sequences with insertions, a 3-base- pair 
insertion at nucleotide positions 2166-2168 in L2 and Shikoku, and a 1 base–pair 
insertion at nucleotide positions 611 in Yunnan-1. Some examples of deletions and 
mutations are shown in Table 4. The sequences of 14 samples listed from the top in 
Table 4, including 6 Japanese samples, 1 Korean sample, and 7 Chinese samples had 
almost identical sequences of 2865 bps. On the other hand, 6 samples had shortened 
sequences due to deletions. Two of them, Korea-3 (Korean Peninsula) and Yunnan-2 
(Yunnan), had a identical sequence of 2823 bps, and the four other samples, Korea-1 
(Korean Peninsula), Shisen (Sichuan), and Anki-1 and -3 (Anhui), also had an identical 
sequence of 2821 bps. Based on this result, we could divide these samples into 3 groups, 
as indicated in Table 3. In addition to deletions, a considerable number of nucleotide 
substitutions were found. Among these substitutions, the nucleotide positions 
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1130-1135 of Group III were TTTAAA, the recognition site of DraI, and that of Group 
I and II were TTTGAA. Furthermore, the nucleotide positions 2001-2006 of Group I 
were AGATCC, whereas those of Group II and III were GGATCC, the recognition site 
of BamHI. Using BamHI or DraI, the restriction fragment length polymorphisms 
(RFLP) of the groups can be observed, as shown in Fig. 2 and 3. Thus, the 
discrimination of 3 groups could be achieved by the combination of RFLPs. Group I 
could be further classified by a notable substitution at nucleotide position 690. All 
Japanese samples, Korea-2 (Korean Peninsula), and Yunnan-1 (Yunnan) had adenine at 
this position, which made a restriction site for DraI (TTTAAA), whereas Sekkou-1 and 
-2 (Zhejiang) and Kishu (Guizhou) had guanine, and Anki-2 (Anhui), Yunnan-3, and 
Yunnan-4 (Yunnan) had adenine and guanine (Table 4). When PCR products amplified 
from the samples using primer set h and i were digested with DraI, these subgroups of 
Group I with adenine were digested whereas those with guanine remained intact and 
with adenine and guanine showed digested and intact signals. Thus, the subgroups could 
be also distinguished by this RFLP (Fig. 4).   
 
Discussion  
We determined the DNA sequences of ITS 1, the 5.8S rRNA gene, ITS 2, and most of 
the 28S rRNA gene of Poria cocos for the first time. Other fungal crude drugs that 
belong to the Polyporaceae, Ganoderma lucidum, and Polyporus umbellatus, were 
reported to have various substitutions in ITS 1 and 29) 10) 11) 12). Although the nucleotide 
lengths of ITS 1 and 2 of Poria cocos samples were remarkably longer than Ganoderma 
and Polyporus, they preserved almost identical sequences in these regions. Some of the 
Poria cocos samples possessed combined sequences, their sequences were 
combinations of the common sequences and those with insertions of 1-3 bps at single 
sites. Thus, ITS 1 and ITS 2 of Poria cocos were quite different from Ganoderma 
lucidum and Polyporus umbellatus in nucleotide length as well as in homogeneity. The 
first fifth of the 28S rRNA gene of the Poria cocos samples, except position 690, was 
also homologous and was similar to the Ganoderma sequence. On the other hand, the 
other part of the 28S rRNA gene could be divided in 3 groups (Group 1, 2, and 3) with 
distinct differences in length and in nucleotide sequence. All of the Japanese cultured 
mycelia samples were classified in Group 1, while the crude drugs from China and 
Korean Peninsula included products of different genotypes. Among the Yunnan samples, 
for example, Yunnan-1, Yunnan-3, and Yunnan-4 had their genotypes classified in 
Group 1, whereas Yunnan-2 was in Group 2. Similarly, 3 cultivated Anhui samples had 
genotypes classified in different groups; Anki-2 in Group 1, and Anki-1 and -3 in Group 
3. These results suggest not only that there are crude drugs with a variety of genotypes 
but also that the current locality of the crude drugs does not guarantee genetic 
uniformity. The inhibitory activity of beta-glucan of Hoelen on cancer cells, one of the 
newly recognized therapeutic potentials of the crude drug, seemed to be different 
between strains13). The traditional concept of quality as well as recently recognized 
efficacy of the crude drug must be discussed when considering their genotype. These 
results of DNA typing of Poria cocos and the methods we propose here will help to 
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Legends for Figures  
 
Fig. 1.  PCR amplification of ITS1 using primer set a and d. 
Lane M : DNA molecular weight marker XIV ( Roche ). Lane 1: Gano-1, Lane 2: 
Gano-2, Lane 3:Chorei, Lane 4: K1, Lane 5: Shikoku, Lane 6: Mikawa, Lane 7: 
Korea-1, Lane 8: Korea-2, Lane 9: Korea-3, Lane 10: Anki-2, Lane 11: Anki-3, Lane 
12: Yunnan-2, Lane 13: Yunnan-1, Lane 14: Shisen, Lane 15: Sekkou-1. 
 
 
Fig. 2.  
The PCR products amplified using primer set k and l, about 600 bps were digested with 
DraI. 
Lane M: DNA molecular weight marker XIV (Roche). Lane 1: K1, Lane 2: Mikawa, 
Lane 3: Shikoku, Lane 4: Korea-2, Lane 5: Yunnan-3, Lane 6: Yunnan-4, Lane 7: Kishu, 
Lane 8: Sekkou1, Lane 9: Anki-2, Lane 10: Korea-3, Lane 11: Yunnan-2, Lane 12: 
Korea-1, Lane 13: Shisen, Lane 14: Anki-1, Lane 15: Anki-3 
 
Fig. 3 Restriction enzyme digestion of PCR products of the 28S rRNA gene. The PCR 
products amplified using primer set k and o, about 2000 bps, were digested with 
BamHI. 
Lane M: DNA molecular weight marker XIV (Roche). Lane 1: K1, Lane 2: Mikawa, 
Lane 3: Shikoku, Lane 4: Korea-2, Lane 5: Yunnan-3, Lane 6: Yunnan-4, Lane 7: Kishu, 
Lane 8: Sekkou1, Lane 9: Anki-2, Lane 10: Korea-3, Lane 11: Yunnan-2, Lane 12: 
Korea-1, Lane 13: Shisen, Lane 14: Anki-1, Lane 15: Anki-3 
 
Fig. 4  Restriction enzyme digestion of PCR products of the 28S rRNA gene of Group I. 
The PCR products amplified using primer set h and i, about 450 bps, were digested with 
DraI.  
Lane M: DNA molecular weight marker XIV ( Roche ). Lane 1: K1, Lane 2: L2, Lane 
3:Mikawa , Lane 4: Shikoku, Lane 5: Korea-2, Lane 6: Yunnan-1, Lane 7: Kishu, 
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Table 1.  Materials Used in This Study 
 




No. Status Origin 
Poria cocos 
Wolf K1 Minowa, Nagano, Japan Nov. 1992  
cultured 
mycelia wild  
 L2 Minowa, Nagano, Japan Nov. 1992  
cultured 
mycelia wild  
 I2 Matsumoto, Nagano, Japan May. 1992  
cultured 
mycelia wild  
 Nagano 15 Shiojiri, Nagano, Japan April. 2005  
cultured 
mycelia wild  
 Mikawa Mikawa, Ishikawa, Japan May. 1993  
cultured 
mycelia wild  
 Shikoku Matsuyama, Ehime, Japan April. 1992  
cultured 
mycelia wild  




drug wild  




drug wild  




drug wild  




















㻃 Sekkou-1㻃 Zhejiang, China  April. 1994  
cultured 
mycelia cultivated 
㻃 㻃 Sekkou-2㻃 Zhejiang, China㻃 April. 1994㻃 㻃
cultured 
mycelia㻃 cultivated 




drug wild  




drug wild  




















lucidum Gano-2 Zhejiang, China Dec. 2006 VPKNR 
crude 
drug cultivated   
Polyporus 
umbellatus  Chorei Shanxi and Gansu, China  Dec. 2006 US312502 
crude 
drug cultivated 
       
 *: Cultured mycelia derived from crude drug, ns: not specified. 
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Table 2   Primers used in this study 
 
 
ID Primer name Sequence 
a Poria ITS1F 5’-CCGTAGGTGAACCTGCAGAA-3’ 
b Poria ITS1W 5’-CGACATTCTCTCTTGAACTCGG-3’ 
c Poria ITS1 850F 5’-GGTACCGTCTTTCTCGATAG-3’ 
d Poria 5.8SR 5’-CGCATTTCGCTGCGTTCTTC-3’ 
e Poria ITS2 200F 5’-GTTGAACGGGAACCCTAGAA-3’ 
f Poria ITS2 nes.R 5’-GGTAGTCCTGCCTGATCTGA-3’ 
g Poria 28SF 5’-AAGATCTCGACTCCGGTTTG-3’ 
h BH Poria 28S500F 5’-ATAAGGATCCAAACGCTTGAAGTCAGTCGC-3’ 
i HD Poria 28S950R 5’-ATATAAGCTTCCTATTCAGGCATAGTTCAC-3’ 
j Poria 28S cent.R 5’-CGATCGATTTGCACGTCAGA-3’ 
k Poria 28S 1000F 5’-CGAAAGATGGTGAACTATGCC-3’ 
l Poria 28S 1600R 5’-GCTACTACCACCAAGATCTG-3’ 
m Poria 28S 2000R 5’-TGCCGACTTCCCTTATCTAC-3’ 
n Poria 28S 2000F 5’-TACTCATAACCGCAGCAGGT-3’ 
o Poria 28S 3000R 5’-AGCCAGTTATCCCTGTGGTA-3’ 
p Poria ITS1 BH 520F 5’-TTTTGGATCCTCTACAGCCATCTTCCGAGT-3’ 
q Poria ITS1 HD 1040R 5’-AAAAAAGCTTTCGCTGCGTTCTTCATCGAT-3’ 
r Poria 28S BH 1900F 5’-ATAAGGATCCAATCGGTTCGTCCGGAGCTA-3’ 






























Table 3     Nucleotide Lengths of the ITS Regions and rRNA Genes 
 
Group Locality (region) Sample IDs ITS1 a) 5.8S b) ITS2 c) 28S
  d) 
K1, I2, Nagano15, 
Mikawa 997 e) 160 f) 460 g) 2865 h) 
460 i) 2865 i) 
L2 997 160 
461 i) 2868 i) 






460 i) Korean 





997 160 460 2865 









Peninsula Korea-3 997 160 460 2823 j Group䊘 
China Yunnan-2 997 160 460 2823 
Korean 
Peninsula Korea-1 997 160 460 2821 Group哿 
China Anki-1, Anki-3, Shisen 997 160 460 2821 k) 
a): Result of sequencing of PCR products amplified using primer sets a and  d, b): result 
of sequenceing of PCR products amplified using primer sets c and  f, c): result of 
sequencing of PCR products amplified using primer sets c and  f, d): result of sequence 
alignment of PCR products amplified using primer sets g and  j, k and m, and n and o, 
e): DDBJ/EMBL/GenBank accession No. EF397596,  f): DDBJ/EMBL/GenBank 
accession No.EF397595, g): DDBJ/EMBL/GenBank accession No. EF397597, h): 
DDBJ/EMBL/GenBank accession No. EF397598, i): determined by cloning, j): 
DDBJ/EMBL/GenBank accession No. EF397599, k): DDBJ/EMBL/GenBank accession 
No. EF397600  
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Table 4    Examples of deletions and mutations in the 28S rRNA gene 
Sample 
name 2103-2114 2149-2152 2166-2168 2569-2571 2632 2641-2643 2670-2676 
K1 TTCGACGGACTC TCCT --- TTA G GGC CTCACCG 
I2 ************ **** --- *** * *** ******* 
L2 ************ **** ---(GGG) *** * *** ******* 
Nagano 15 ************ **** --- *** * *** ******* 
Shikoku ************ **** ---(GGG) *** * *** ******* 
Mikawa ************ **** --- *** * *** ******* 
Korea-2 ************ **** --- *** * *** ******* 
Yunnan-1 ************ **** --- *** * *** ******* 
Anki-2 ************ **** --- *** * *** ******* 
Kishu ************ **** --- *** * *** ******* 
Sekkou-1 ************ **** --- *** * *** ******* 
Sekkou-2 ************ **** --- *** * *** ******* 
Yunnan-4 ************ **** --- *** * *** ******* 
Yunnan-3 ************ **** --- *** * *** ******* 
Korea-3 ------------ ---- GGC --- - --- ------- 
Yunnan-2 ------------ ---- GGC --- - --- ------- 
Korea-1 ------------ ---- GGC --- - --- ------- 
Anki-1 ------------ ---- GGC --- - --- ------- 
Anki-3 ------------ ---- GGC --- - --- ------- 
Shisen ------------ ---- GGC --- - --- ------- 
*: same as the top column, -: deletion, R: adenine/guanine. 
Sample 
name 611 690 1058 1106 1168 1467 1642-1643 1654-1655 1714 1785-1787 2082 
K1 - A C T - T TC CC G CGC T 
I2 - * * * - * ** ** * ***   * 
L2 - * * * - * ** ** * *** * 
Nagano 15 - * * * - * ** ** * *** * 
Shikoku - * * * - * ** ** * *** * 
Mikawa - * * * - * ** ** * *** * 
Korea-2 - * * * - * ** ** * *** * 
Yunnan-1 -(T) * * * - * ** ** * *** * 
Anki-2 - G * * - * ** ** * *** * 
Kishu - G * * - * ** ** * *** * 
Sekkou-1 - G * * - * ** ** * *** * 
Sekkou-2 - R * * - * ** ** * *** * 
Yunnan-4 - R * * - * ** ** * *** * 
Yunnan-3 - R * * - * ** ** * *** * 
Korea-3 - R * * - * -- -- - --- - 
Yunnan-2 - R * * - * -- -- - --- - 
Korea-1 - R - - T - -- -- - --- - 
Anki-1 - R - - T - -- -- - --- - 
Anki-3 - R - - T - -- -- - --- - 
Shisen - R - - T - -- -- - --- - 
